China Securities Regulatory Commission rarely made a heavy voice at the opening time. It is very concerned about the delisting risk faced by zhonggai shares.
This morning, the A-share Hong Kong stock market as a whole was shocked and depressed, while traditional stocks such as real estate stocks and bank stocks strongly supported the market, and real estate stocks were in the trend of daily limit; The previously popular lithium battery track stocks plunged and collapsed the gem; Photovoltaic also fell sharply, semiconductor fell sharply, with bengkechuang board; Smore international, the leading e-cigarette stock of more than 100 billion, collapsed after the release of performance, and the new shares broke again. The first signing may lose 2000 yuan. Among covid-19 concept stocks, two popular bull stocks with a market value of about 50 billion, China Meheco Group Co.Ltd(600056) , Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) pulled the limit again.
At the close of the morning, the main indexes are green, and the gem and the science and innovation board are all the way down, with a significant decline. The Shanghai Composite Index fell slightly by 0.1%, the Shenzhen composite index fell by 1.01%, the gem index fell by 1.45%, and the Kechuang 50 index fell by 1.74%. The turnover between the two cities was 619.3 billion yuan, 2172 stocks fell and 2437 stocks rose.
In the morning, Shanghai Stock connect net bought, Shenzhen Stock connect net outflow, and northbound capital net bought more than 500 million yuan.
China Securities Regulatory Commission issued a heavy voice at the rare opening time: response to whether China concept shares will be delisted
At the opening of A-Shares in the morning, the China Securities Regulatory Commission rarely made a heavy voice at this time point to respond to the question of whether stocks in the United States and China will face delisting.
China Securities Regulatory Commission said that it was learned from the US SEC that it was a normal procedure for the US regulatory authorities to implement the foreign company Accountability Act for some enterprises listed in the list of delisting risks by the sec. Whether the listed companies really delisted in the next two years ultimately depends on the progress and results of China US audit and supervision cooperation.
The questions and answers issued by the CSRC are as follows:
Q: what is the CSRC’s comment on the recent concerns of the chairman of the securities and Exchange Commission (SEC) on China US audit supervision cooperation?
A: we have taken note of the statement made by the chairman of the US SEC on the cooperation between the two sides in auditing and supervision in a recent media television interview. As Mr Gensler said, the regulatory authorities of the two sides had a thoughtful, mutual respect and fruitful dialogue. Since August last year, chairman Yi Huiman and chairman Gensler of China Securities Regulatory Commission have held three video conferences to discuss and solve the remaining problems in China US audit and supervision cooperation. China and the public company accounting oversight board of the United States (PCAOB) have held several rounds of frank, professional and efficient talks, which are generally progressing smoothly, and the communication between the two sides will continue. Both sides are willing to resolve differences and problems. The final outcome depends on the wisdom and original intention of both sides.
In addition, for some enterprises listed in the delisting risk list by the SEC, it is learned from the SEC that this is a normal procedure for the U.S. regulatory authorities to implement the foreign company Accountability Act. Whether the listed companies really delist in the next two years ultimately depends on the progress and results of China US audit and regulatory cooperation.
The CSRC responded that on Wednesday local time, the U.S. Securities and Exchange Commission added Baidu, futu holdings, iqiyi, Kaixin Yuanda medicine and Nocera engaged in fishery breeding to the “pre delisting list”, which is also the third batch of zhonggai shares included in the list since March. According to the SEC, the five companies need to provide evidence to the sec before April 20 to prove that they do not have the conditions to be delisted; If it cannot be proved, it will be included in the “confirmed delisting list”.
Some companies have responded urgently. Futu Holdings said that as a global digital financial technology company, its American depositary shares are listed on the Nasdaq stock market. The company has been paying close attention to the relevant requirements of the US foreign company Accountability Act (hfcaa) and assessing its potential impact on the company, and actively exploring plans to maintain the company’s listing status.
two 50 billion covid-19 concept bull stocks rose again
Although the overall market is flat and weak, some sectors and individual stocks are still very strong. Covid-19 drug concept rose well in the morning, especially the two big bull stocks with a market value of about 50 billion, China Meheco Group Co.Ltd(600056) , Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) rose again.
As an operator introducing Pfizer covid-19 special drug, China Meheco Group Co.Ltd(600056) share price continued to break out. After opening high this morning, it quickly hit the limit, with a market value of 47.3 billion yuan. The stock has been trading for three consecutive times, and the stock price also continued to rise before.
In March 9th, China Meheco Group Co.Ltd(600056) signed a commercial operation agreement with Pfizer on Pfizer Inc’s COVID-19 virus treatment Paxlovid in Chinese mainland market.
On the late night of March 16, 21200 boxes of imported covid-19 virus treatment drug “paxlovid” arrived at Shanghai Pudong Airport by air from Belgium. After being checked and released by the customs of Shanghai Shanghai Waigaoqiao Free Trade Zone Group Co.Ltd(600648) Free Trade Zone, all import customs clearance procedures were completed and transported to China Meheco Group Co.Ltd(600056) Daxing logistics center.
According to the latest report of Jingshi news, at present, Pfizer covid-19 oral drug nimatovir tablets / ritonavir tablets combined packaging (i.e. paxlovid) is put into use in Zhejiang, with a price of 2300 yuan / box and included in medical insurance.
After the product Lianhua Qingwen capsule was included in the covid-19 diagnosis and treatment plan, the share price of Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) also continued to break out. It rose again this morning, and the market value reached 56.4 billion yuan, a record high.
real estate stocks set off a wave of limit, and coal of pharmaceutical bank also rose sharply
In terms of industry sectors, the real estate sector led the rise, while medicine, banking and coal also rose.
Real estate stocks set off a wave of limit trading, with Tianjin Realty Development (Group) Co.Ltd(600322) , Tianjin Hi-Tech Development Co.Ltd(600082) , Yang Guang Co.Ltd(000608) , Cinda Real Estate Co.Ltd(600657) , etc.
popular lithium photovoltaic chips and other track diving
Previously, lithium batteries, photovoltaic and chips in popular tracks plunged one after another, which also led to a significant decline in the gem and the science and innovation board.
The Youngy Co.Ltd(002192) , Sinomine Resource Group Co.Ltd(002738) , Yongxing Special Materials Technology Co.Ltd(002756) of lithium ore all fell by more than 7%; The Guangzhou Great Power Energy&Technology Co.Ltd(300438) , Ningbo Ronbay New Energy Technology Co.Ltd(688005) , etc. of lithium batteries also fell sharply, and the Contemporary Amperex Technology Co.Limited(300750) of lithium battery giant also fell sharply by 2.83%.
new shares broke again, and the first signing lost 2000 yuan
Although n Rongchang, a new share listed on the A-share market today, is the “Darling” of innovative drugs, it still broke. It closed down 8.29% in the morning, with a share down 3.98 yuan. The new shares on the science and Innovation Board signed 500 shares, and the first batch lost about 2000 yuan.
Rongchang Biology (n Rongchang) has a share price of 48 yuan / share and plans to raise 4 billion yuan, which will be used for biological new drug industrialization project, anti-tumor antibody new drug research and development project, autoimmune and ophthalmic disease antibody new drug research and development project and supplementary working capital.
100 billion Star stock smore collapsed, and Hansen pharmaceutical also plummeted
Hong Kong stocks also fell significantly in the morning, and star stocks smore international and Hansen pharmaceutical all collapsed and plummeted.
After the results were released last night, although the performance increased well, SIMORE international suddenly collapsed and plummeted at the opening, with a sharp drop of 11.83% in the morning, and the market value of the company was HK $115.5 billion.
Yesterday, smalls International released its 2021 annual performance announcement. During the review period, the group’s total revenue was about 13.755.2 billion yuan, an increase of about 37.4% over the previous year. The gross profit was about RMB 7.377 billion, an increase of about 39.3% over the same period last year, and the gross profit margin was about 53.6% (2020: 52.9%). The total profit and comprehensive income of the group during the year increased from about RMB 2399.9 million in 2020 to about RMB 5287 million this year. The adjusted net profit was about 5.442.6 billion yuan, an increase of 39.8% over the previous year.
The main reasons for the increase include the increase of income and the increase of gross profit margin due to cost reduction and efficiency increase. The board of directors intends to declare a final dividend of HK $18 per ordinary share for the year ended December 31, 2021.
Star Pharmaceutical Stock Hansen pharmaceutical plunged about 15%.
